| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MICA |
| Uniprot No | Q29983 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 24-308aa |
| 氨基酸序列 | EPHSLRYNLTVLSWDGSVQSGFLTEVHLDGQPFLRCDRQKCRAKPQGQWA EDVLGNKTWDRETRDLTGNGKDLRMTLAHIKDQKEGLHSLQEIRVCEIHE DNSTRSSQHFYYDGELFLSQNLETKEWTMPQSSRAQTLAMNVRNFLKEDA MKTKTHYHAMHADCLQELRRYLKSGVVLRRTVPPMVNVTRSEASEGNITV TCRASGFYPWNITLSWRQDGVSLSHDTQQWGDVLPDGNGTYQTWVATRIC QGEEQRFTCYMEHSGNHSTHPVPSGKVLVLQSHWQ |
| 预测分子量 | 34 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于MICA重组蛋白的代表性文献(信息基于公开研究整理，非实时更新)：
---
1. **文献名称**: *Soluble MICA proteins generated by tumor cells evade NK cell-mediated immunosurveillance*
**作者**: Salih HR, et al.
**摘要**: 研究报道肿瘤细胞通过分泌可溶性MICA蛋白逃逸NK细胞杀伤，团队通过重组MICA胞外段蛋白表达，证明其与NKG2D受体结合后抑制免疫反应，为肿瘤免疫治疗提供靶点。
---
2. **文献名称**: *Expression and purification of functional recombinant MICA for studies of antibody-dependent cellular cytotoxicity*
**作者**: Zhang Y, et al.
**摘要**: 描述利用哺乳动物表达系统(如HEK293细胞)高效表达重组MICA蛋白，并通过亲和层析纯化获得高纯度蛋白，用于验证抗体依赖性细胞毒性(ADCC)相关抗体的功能。
---
3. **文献名称**: *Structural basis for NKG2D recognition of MICA/B in viral infection and cancer*
**作者**: Rölle A, et al.
**摘要**: 通过X射线晶体学解析重组MICA蛋白与NKG2D受体的复合物结构，揭示病毒感染和肿瘤中MICA构象变化如何影响免疫识别机制，为设计免疫调节药物提供结构依据。
---
**备注**：如需获取全文或最新研究，建议通过PubMed或ResearchGate检索关键词“recombinant MICA protein”并筛选近5年文献，重点关注《Nature Immunology》《Journal of Immunology》等期刊。
MICA (MHC class I polypeptide-related sequence A) is a stress-inducible cell surface glycoprotein belonging to the MHC class I family. Unlike classical MHC class I molecules, MICA does not present antigens but functions as a ligand for the activating receptor NKG2D, expressed on natural killer (NK) cells, γδ T cells, and CD8+ αβ T cells. Its expression is typically low in healthy tissues but upregulated in response to cellular stress, infection, or malignant transformation, making it a critical mediator of innate and adaptive immune responses against infected or cancerous cells.
Structurally, MICA consists of three extracellular domains (α1. α2. α3), a transmembrane region, and a cytoplasmic tail. Polymorphisms in the MICA gene influence protein expression and receptor binding affinity, contributing to variations in immune responses. In cancer, tumor cells often evade immune surveillance by proteolytic shedding of MICA, releasing soluble forms (sMICA) that downregulate NKG2D on immune cells, thereby impairing cytotoxicity.
Recombinant MICA proteins are engineered to study these interactions and develop therapeutic strategies. Produced via expression systems (e.g., mammalian, insect cells), they retain functional epitopes for NKG2D binding and are used in immunological assays, structural studies, and as reagents to block sMICA-mediated immunosuppression. Researchers also explore recombinant MICA in immunotherapy, such as vaccines or bispecific antibodies, to enhance NKG2D-mediated tumor targeting. Additionally, recombinant MICA aids in diagnosing and monitoring diseases by quantifying sMICA levels, which correlate with cancer progression and prognosis.
Overall, recombinant MICA serves as a vital tool for understanding immune evasion mechanisms and advancing immunotherapies aimed at restoring NKG2D-dependent immune surveillance.
×
